

# Faramarz Ismail-Beigi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2947670/publications.pdf>

Version: 2024-02-01

45  
papers

3,013  
citations

361296

20  
h-index

265120

42  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4283  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010, 376, 419-430.	6.3	1,182
2	The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. <i>Ophthalmology</i> , 2014, 121, 2443-2451.	2.5	239
3	Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). <i>Scientific Reports</i> , 2017, 7, 13461.	1.6	201
4	Glycemic Management of Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2012, 366, 1319-1327.	13.9	142
5	Protective hinge in insulin opens to enable its receptor engagement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3395-404.	3.3	142
6	A View Beyond HbA1c: Role of Continuous Glucose Monitoring. <i>Diabetes Therapy</i> , 2019, 10, 853-863.	1.2	116
7	Overexpression of stomatin depresses GLUT-1 glucose transporter activity. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 280, C1277-C1283.	2.1	103
8	Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1343-1352.	2.2	85
9	Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Advances in Therapy</i> , 2020, 37, 4697-4708.	1.3	81
10	Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Diabetes Therapy</i> , 2021, 12, 843-861.	1.2	72
11	&lt;p&gt;Glucocorticoid-Induced Fatty Liver Disease&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1133-1145.	1.1	70
12	Mutations of Peripheral Myelin Protein 22 Result in Defective Trafficking through Mechanisms Which May Be Common to Diseases Involving Tetraspan Membrane Proteins&€€. <i>Biochemistry</i> , 2001, 40, 9453-9459.	1.2	67
13	Metabolic programming: fetal origins of obesity and metabolic syndrome in the adult. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E439-E440.	1.8	55
14	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	2.6	53
15	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	4.3	33
16	An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein. <i>Journal of Biological Chemistry</i> , 2018, 293, 47-68.	1.6	32
17	Evolution of insulin at the edge of foldability and its medical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29618-29628.	3.3	30
18	Disturbances in Insulin&€€Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4949-4966.	1.8	27

#	ARTICLE	IF	CITATIONS
19	Aromatic Anchor at an Invariant Hormone-Receptor Interface. <i>Journal of Biological Chemistry</i> , 2014, 289, 34709-34727.	1.6	25
20	&lt;p&gt;SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1001-1012.	1.1	23
21	Biophysical Optimization of a Therapeutic Protein by Nonstandard Mutagenesis. <i>Journal of Biological Chemistry</i> , 2014, 289, 23367-23381.	1.6	20
22	Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. <i>Archives of Iranian Medicine</i> , 2012, 15, 239-46.	0.2	19
23	Prolonged Exposure to Insulin Inactivates Akt and Erk1/2 and Increases Pancreatic Islet and INS1E $\beta$ -Cell Apoptosis. <i>Journal of the Endocrine Society</i> , 2019, 3, 69-90.	0.1	17
24	Na,K-ATPase mRNA $\beta$ 1 expression in rat myocardium - effect of thyroid status. <i>FEBS Journal</i> , 1999, 260, 1-8.	0.2	16
25	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	4.3	16
26	Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran. <i>Canadian Journal of Diabetes</i> , 2020, 44, 246-252.	0.4	14
27	Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 113.	0.7	13
28	Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1181-1189.	0.8	12
29	Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding. <i>Journal of Biological Chemistry</i> , 2018, 293, 69-88.	1.6	12
30	Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). <i>Primary Care Diabetes</i> , 2020, 14, 222-231.	0.9	12
31	Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin. <i>Diabetes</i> , 2020, 69, 1815-1826.	0.3	12
32	Shape of the OGTT glucose response curve: relationship with $\beta$ -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002264.	1.2	12
33	â€œRegister-shiftâ€•insulin analogs uncover constraints of proteotoxicity in protein evolution. <i>Journal of Biological Chemistry</i> , 2020, 295, 3080-3098.	1.6	11
34	Reassessment of an Innovative Insulin Analogue Excludes Protracted Action yet Highlights the Distinction between External and Internal Diselenide Bridges. <i>Chemistry - A European Journal</i> , 2020, 26, 4695-4700.	1.7	11
35	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trialâ€™Clinical Implications. <i>Clinical Chemistry</i> , 2011, 57, 261-263.	1.5	8
36	Glycemia Management and Cardiovascular Risk in Type 2 Diabetes: An Evolving Perspective. <i>Endocrine Practice</i> , 2008, 14, 639-643.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. <i>Advances in Therapy</i> , 2020, 37, 3450-3462.	1.3	6
38	Association of glycemia with insulin sensitivity and $\beta$ -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	1.2	5
39	Study rationale and design of a study of EMPAgliflozin <sup>™</sup> 's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 318.	0.7	5
40	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 682-690.	2.4	4
41	Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation. <i>Frontiers in Endocrinology</i> , 2022, 13, 821069.	1.5	3
42	Human radiation dosimetry of $^{18}\text{F}$ FDG predicted from preclinical studies. <i>Medical Physics</i> , 2014, 41, 031910.	1.6	1
43	Risk of Insulin Accumulation (Stacking) with use of Novel Ultralong-Acting Insulin Formulation. <i>Endocrine Practice</i> , 2014, 20, 990-991.	1.1	0
44	Insulin induces a desensitization of insulin and IGF <sup>1</sup> signaling in INS1 <sup>+</sup> beta cells: Mechanisms and consequences on function and survival. <i>FASEB Journal</i> , 2006, 20, A1170.	0.2	0
45	Impact of quality mentorship on achievements of Shiraz Medical School in the 1970s and the role of Professors Khosrow Nasr and Asghar Rastegar. <i>Archives of Iranian Medicine</i> , 2013, 16, 251-3.	0.2	0